![]() |
市场调查报告书
商品编码
1828105
2025年全球显影剂注射器市场报告Contrast Media Injectors Global Market Report 2025 |
近年来,显影剂注射器市场呈现强劲成长势头,市场规模从2024年的16.8亿美元成长至2025年的17.7亿美元,复合年增长率达5.7%。预测期内的成长主要受多种因素驱动,例如慢性病盛行率的上升、诊断影像程序数量的增加、对微创手术的需求、医疗基础设施的扩展以及人口老化。
预计未来几年显影剂注射器市场将强劲成长,到2029年将达到24.9亿美元,复合年增长率为8.9%。预测期内的成长归因于介入性放射学手术的兴起、癌症盛行率的上升、对病人安全和舒适度的重视、医疗服务的全球化以及法规支持和合规性。预测期内的主要趋势包括自动化和连结性、双头注射器的出现、注射器技术的进步、对病人安全的重视、介入放射学手术的兴起以及成像技术和模式的改进。
显影剂注射器是一种先进的医疗设备,旨在註射显影剂以增强医学影像处理中的组织可见性,确保卓越的精确度和准确度,从而获得最佳的手术效果。
显影剂注射器市场的关键产品包括耗材、注射器系统和配件。耗材,即医用注射器,在防止破损和洩漏、防止潜在伤害、注射器停机以及其他不良事件方面发挥着至关重要的作用。这些注射器对于安全、无耗材的诊断成像至关重要。市场提供各种类型的注射器,包括单头注射器、双头注射器和无针头注射器,专为放射学、介入性心臟病学和介入放射学应用而设计。它们广泛应用于医院、诊断中心和门诊手术中心,满足医疗专业人员的多样化需求,并有助于提高诊断影像的准确性和诊断能力。
2025年春季美国关税大幅上调及其引发的贸易摩擦对医疗设备产业产生了重大影响,尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制价格上涨,製造商面临利润压力。监管挑战进一步加剧了形势,因为由于关税而更换供应商通常需要医疗设备重新认证,导致市场进入延迟。为此,企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。
本研究报告是商业研究公司新报告系列的一部分,该系列提供显影剂市场统计数据,包括全球市场规模、区域份额、显影剂市场份额的竞争对手、详细的显影剂细分市场、市场趋势和商业机会,以及在显影剂显影剂取得成功所需的数据。这份显影剂市场研究报告对行业当前和未来情况进行了详细分析,为您提供所需的一切的完整观点。
未来五年8.9%的预测成长率,较我们先前对该市场的预测略有下降,下降了0.2%。下降的主要原因是美国与其他国家之间关税的影响。这一影响将直接影响美国,导致来自奥地利和丹麦等主要地区的精密注射式帮浦和一次性压力管的供应链中断,可能导致影像处理检查延误和放射学成本上升。由于互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响,这种影响将更加广泛。
显影剂注射器市场的预期成长是由癌症和心血管疾病 (CVD) 日益增长的盛行率所推动的。以不受控制的细胞生长和增殖为特征的癌症和影响心臟和血管的 CVD 是市场的主要驱动力。显影剂在诊断影像、改善影像品质、病患安全以及血流和组织灌注方面发挥关键作用。值得注意的是,美国癌症协会的统计数据显示,癌症病例数将从 2021 年的 1,898,160 例增加 3.16% 到 2023 年 1 月的 1,958,310 例。此外,世界心臟联盟报告称,到 2023 年 4 月,全球将有超过 5 亿人患心血管疾病,2021 年死亡人数将达到 2,050 万,占全球死亡总数的近三分之一。癌症和心血管疾病患者数量的快速成长是显影剂注射器市场的主要驱动力。
预计未来对非侵入性诊断程序不断增长的需求将推动显影剂注射器市场的成长。非侵入性诊断程序是一种不需要透过天然或人工孔口进入体内或涉及皮肤穿透的医学检查或治疗。显影剂在非侵入性诊断程序中起着关键作用,特别是在电脑断层扫描 (CT) 和磁振造影(MRI) 等影像方式中。例如,根据英国国民医疗服务体系 (NHS) 2023 年 5 月的数据,2023 年 1 月最常用的成像方式是普通放射线照相 (X 射线),共进行了 165 万次,其次是诊断性超音波(超声波),共进行了 810,000 次,磁振造影断层扫描 (CT) 扫描,共进行了310,000 次。因此,对非侵入性诊断程序不断增长的需求正在推动显影剂注射器市场的成长。
策略联盟是显影剂注射器市场的一大趋势。该领域的主要企业正在积极合作,以建立新的合作关係,尤其是在类似产品开发方面。例如,比利时先进剂量和造影管理软体解决方案提供商 Qaelum NV 与法国手术器械製造商和经销商Ulrich GmbH & Company KG 之间的合作。透过整合资源,两家公司旨在将 Qaelum NV 的先进显影剂管理解决方案与 Ulrich Medical 的显影剂相结合,以满足医院和诊断影像网路的需求。这种伙伴关係模式反映了业界致力于加强合作、实现互利共赢的决心。
显影剂注射器市场的主要参与企业正专注于开发创新产品,例如非专利显影剂剂注射器。这些含有显影剂的药物在增强电脑断层扫描和 MRI 等医学影像过程中的可视性方面发挥着至关重要的作用。值得注意的是,总部位于德国的製药公司费森尤斯卡比 (Fresenius Kabi) 于 2023 年 8 月推出了两种新药。第一种是钆布醇注射液,是一种专为 MRI 设计的钆基显影剂,扩展了费森尤斯卡比的放射学产品组合。第二种是普乐沙福注射液,是一种造血干细胞动员剂,是费森尤斯卡比广泛的可注射癌症治疗非专利系列的补充。这种对策略产品创新的关注凸显了该产业对竞争和扩大基本客群的承诺。
2022年11月,美国知名製造公司GE医疗科技集团与Ulrich GmbH & Co. KG达成伙伴关係。此次合作的主要目标是将多剂量显影剂引入美国市场,并加强CT运动注射器的销售。 Ulrich GmbH & Co. KG总部位于法国,专门从事脊椎系统和显影剂注射器的开发、製造和销售。此次合作体现了GE医疗科技集团的策略方针,即透过利用合作伙伴的专业知识来扩大其市场占有率并增强其产品供应,尤其是在显影剂注射器领域。
显影剂市场的主要企业包括 Bracco Group、Bayer AG、Medtron AG、Ulrich GmbH And Co.KG、通用电气公司、Nemoto Kyorindo Co. Ltd.、Guerbet Group、Sino Medical-Device Technology Co. Ltd、Apollo RT Co.Ltd、深圳安科高科技股份有限公司、Vivid ITic、Thio. Co.Ltd.、Medtronic Plc、ACIST Medical Systems、波士顿科学公司、Mallinckrodt Pharmaceuticals、Lantheus Medical Imaging Inc. 和 Imaxeon Pty Ltd。
2024年,北美是显影剂注射器市场最大的地区。根据全球显影剂市场报告,预计亚太地区在预测期内将成为成长最快的地区。显影剂注射器市场报告涵盖以下地区:亚太地区、西欧、中欧和东欧、北美、南美以及中东和非洲。
显影剂市场报告涵盖的国家:澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国、美国、加拿大、义大利、西班牙
显影剂注射器市场包括 Empower CTA+、液压磁振造影注射器、电脑断层扫描 (CT) 注射器和注射器设备的销售。此市场的价值是指“出厂价”,即商品製造商或生产商向其他营业单位(包括下游製造商、批发商、经销商和零售商)或直接向最终客户销售的商品价值。该市场的商品价值还包括商品製造商提供的任何相关服务。
Contrast media injectors are advanced medical devices designed for administering contrast media to enhance tissue visibility in medical imaging procedures, ensuring superior accuracy and precision for optimal surgical outcomes.
The primary offerings in the contrast media injectors market include consumables, injector systems, and accessories. Consumables, also known as medical injectors, play a pivotal role in safeguarding against breaks or leaks that could lead to potential harm, injector downtime, or other undesirable incidents. These injectors are integral for conducting safe and consumable imaging procedures in diagnostics. The market features various types of injectors, including single head injectors, dual-head injectors, and syringeless injectors, tailored for applications in radiology, interventional cardiology, and interventional radiology. They find widespread usage in hospitals, diagnostics centers, and ambulatory surgery centers, catering to the diverse needs of medical professionals and contributing to the advancement of imaging precision and diagnostic capabilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The contrast media injectors market research report is one of a series of new reports from The Business Research Company that provides contrast media injectors market statistics, including contrast media injectors industry global market size, regional shares, competitors with a contrast media injectors market share, detailed contrast media injectors market segments, market trends and opportunities, and any further data you may need to thrive in the contrast media injectors industry. This contrast media injectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The contrast media injectors market size has grown strongly in recent years. It will grow from $1.68 billion in 2024 to $1.77 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increased incidence of chronic diseases, increased diagnostic imaging procedures, demand for minimally invasive procedures, expansion of healthcare infrastructure, growing aging population.
The contrast media injectors market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to rise in interventional radiology procedures, increasing prevalence of cancer, focus on patient safety and comfort, globalization of healthcare services, regulatory support and compliance. Major trends in the forecast period include automation and connectivity, emergence of dual-head injectors, advancements in injector technology, focus on patient safety, rise in interventional radiology procedures, enhanced imaging techniques and modalities.
The forecast of 8.9% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for precision syringe pumps and disposable pressure tubing, sourced from key regions such as Austria and Denmark, which could lead to imaging procedure delays and increased radiology department expenses.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated growth of the contrast media injectors market is set to be propelled by the increasing incidence of cancer and cardiovascular diseases (CVD). Cancer, characterized by uncontrolled cell growth and dissemination, and CVD, impacting the heart or blood vessels, are driving factors for the market. Contrast media injectors play a crucial role in diagnostic imaging, enhancing image quality, ensuring patient safety, and improving blood flow and tissue perfusion. Notably, statistics from the American Cancer Society reveal a 3.16% growth in cancer cases from 1,898,160 in 2021 to 1,958,310 in January 2023. Additionally, the World Heart Federation reports that over 500 million individuals globally will be affected by cardiovascular diseases in April 2023, leading to 20.5 million fatalities in 2021, constituting nearly one-third of total global mortality. This surge in cancer and CVD cases is a significant driver for the contrast media injectors market.
The increasing demand for non-invasive diagnostic procedures is anticipated to drive the growth of the contrast media injectors market in the future. Non-invasive diagnostic procedures are medical examinations or treatments that do not require physical entry into the body through natural or artificial openings or involve skin penetration. Contrast media injectors play a crucial role in non-invasive diagnostic methods, particularly in imaging techniques such as computed tomography (CT) scans and magnetic resonance imaging (MRI). For example, in May 2023, the National Health Service (NHS) England reported that in January 2023, plain radiography (X-ray) was the most frequently used imaging technique, with 1.65 million procedures performed. This was followed by diagnostic ultrasonography (Ultrasound) at 0.81 million, computerized axial tomography (CT scan) at 0.52 million, and magnetic resonance imaging (MRI) at 0.31 million. Therefore, the growing demand for non-invasive diagnostic procedures is propelling the growth of the contrast media injectors market.
Strategic partnerships are emerging as a prominent trend within the contrast media injectors market. Major companies in this sector are actively engaging in collaborations to foster new relationships, particularly those involving similar product developments. An illustrative example is the collaboration between Qaelum NV, a Belgium-based provider of advanced dose and contrast management software solutions, and Ulrich GmbH & Company KG, a France-based surgical instruments manufacturer and distributor. By pooling their resources, these companies aim to integrate Qaelum NV's advanced contrast management solution with Ulrich Medical's contrast media injectors, thereby addressing the requirements of hospitals and imaging networks. This partnership model demonstrates the industry's commitment to enhancing collaborative efforts for mutual benefit.
Key players in the contrast media injector market are directing their efforts towards the development of innovative products, such as generic contrast media injectables. These pharmaceutical products, containing contrast agents, play a pivotal role in enhancing visibility during medical imaging procedures such as CT scans and MRIs. Notably, Fresenius Kabi, a Germany-based pharmaceutical company, introduced two novel drugs in August 2023. The first, Gadobutrol Injection, is a gadolinium-based contrast agent tailored for MRI use, expanding Fresenius Kabi's radiology portfolio. The second, Plerixafor Injection, serves as a hematopoietic stem cell mobilizer, complementing the company's extensive collection of generic injectable oncology medicines. This strategic focus on product innovation underscores the industry's commitment to gaining a competitive edge and broadening its customer base.
In November 2022, GE HealthCare Technologies Inc., a prominent US-based manufacturing company, entered into a partnership with Ulrich GmbH & Co. KG. The primary objective of this collaboration is to introduce multi-dose contrast media injectors in the U.S. market and bolster the sales of CT motion injectors. Ulrich GmbH & Co. KG., based in France, specializes in the development, production, and distribution of spinal systems and contrast medium injectors. This collaboration exemplifies GE HealthCare Technologies Inc.'s strategic approach to expanding its market presence and leveraging the expertise of partners to enhance its product offerings, particularly in the realm of contrast media injectors.
Major companies operating in the contrast media injectors market include The Bracco Group, Bayer AG, Medtron AG, Ulrich GmbH And Co. KG, General Electric Company, Nemoto Kyorindo Co. Ltd., Guerbet Group, Sino Medical-Device Technology Co. Ltd, Apollo RT Co.Ltd, Shenzhen Anke High-tech Co. Ltd, Vivid Imaging, AngioDynamics. Inc., Medrad Inc., TaeWoong Medical Co. Ltd., Medtronic Plc, ACIST Medical Systems, Boston Scientific Corporation, Mallinckrodt Pharmaceuticals, Lantheus Medical Imaging Inc., Imaxeon Pty Ltd.
North America was the largest region in the contrast media injectors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global contrast media injectors market report during the forecast period. The regions covered in the contrast media injectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the contrast media injectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The contrast media injectors market consists of sales of empower CTA+, hydraulic-powered MR injectors, computed tomography (CT) injectors, and syringe devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Contrast Media Injectors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on contrast media injectors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for contrast media injectors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The contrast media injectors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.